Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives
Fudan University · Huashan Hospital
Indexed incrossrefdoajpubmed
Abstract
Hepatocellular carcinoma (HCC) is a major health concern worldwide, with limited therapeutic options and poor prognosis. In recent years, immunotherapies such as immune checkpoint inhibitors (ICIs) have made great progress in the systemic treatment of HCC. The combination treatments based on ICIs have been the major trend in this area. Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective treatment for advanced HCC. However, the majority of HCC patients obtain limited benefits. Understanding the immunological rationale and exploring novel ways to improve the efficacy of immunotherapy has drawn much attention. In this review, we summarize the latest…
Citation impact
186
total citations
- FWCI
- 48.37
- Percentile
- 100%
- References
- 230
Citations per year
Authors
4Topics & keywords
Topics
Keywords
- Tremelimumab
- Durvalumab
- Medicine
- Immunotherapy
- Hepatocellular carcinoma
- Oncolytic virus
- Immune checkpoint
- Immunology
No related works found for this paper.